Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1

Interventions

Cyclophosphamide 103fludarabine 61Methotrexate 49Dexamethasone 46fludarabine phosphate 45Cytarabine 45Vincristine 42blinatumomab 36Whole-Body Irradiation 33Mycophenolic Acid 30Tacrolimus 26Mercaptopurine 26Melphalan 26venetoclax 24Specimen Handling 24Etoposide 23Peripheral Blood Stem Cell Transplantation 21pegaspargase 20Stem Cell Transplantation 19Granulocyte Colony-Stimulating Factor 19Calcium Dobesilate 19Busulfan 19Doxorubicin 18Prednisone 17Rituximab 16Filgrastim 16Daunorubicin 16Asparaginase 16merphos 15Thiotepa 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma × BEBT-908 × 1 year × Clear all
NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

Ruijin Hospital

Phase 2 Not yet recruiting
23 enrolled
LymphoidOther hematologic neoplasm

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡